---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034430"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:35:57.312309+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allurion Q4 2023 revenue drops to $8.2M from $19.2M; operating loss widens to $25.7M

## Summary
- Q4 2023 revenue $8.2M (down 57% YoY); full year 2023 revenue $53.5M.
- Q4 operating loss $25.7M vs $10.1M in Q4 2022, driven by $7M AR reserves and $3M stock comp.
- Cash and equivalents $38M at Dec 31, 2023; targeting ~$30M cash burn for 2024.
- Reiterates 2024 guidance: revenue $60-65M, 20% procedural volume growth, 77-79% gross margins.
- Completed AUDACITY pivotal trial enrollment for FDA PMA; first UK NHS reimbursed patients treated.

## SEC filing metadata
- accession: 0000950170-24-034430
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/0000950170-24-034430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000095017024034430/alur-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034430
- JSON: https://secwatch.observer/filing/0000950170-24-034430.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.